Bisnis.com, JAKARTA — Sluggish domestic demand, higher prices for imported raw materials, and high operational costs have taken a toll on the performance of several pharmaceutical companies in H1/2025.
These challenges led to mixed financial results among Indonesia’s pharmaceutical issuers during the period, with some managing to post gains in sales and net profit, while others continued to struggle under the weight of rising expenses and tepid demand.